Q-omics provides the consensus-scored TYMS profile across patient tissues and cancer cell-line models. TYMS expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TYMS is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, TYMS protein abundance shows 21,843 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, KIRC, and LUAD as cancer lineages where TYMS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TYMS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TYMS survival associations across molecular data types. TYMS RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TYMS RNA expression–survival associations across cancer types. High TYMS expression shows unfavorable associations in ACC, MESO, LIHC, KICH and LGG, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TYMS RNA expression.
This table summarizes TYMS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TYMS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TYMS shows higher tumor expression in KIRC, BLCA, LUAD, KIRP, HNSC and THCA. The KIRC box plot shows higher TYMS RNA expression in tumor versus normal tissue (log2 FC = +2.403, t-test p < 0.001).
This table shows molecular features associated with TYMS in patient tissues and cancer cell lines. In patient samples, TYMS shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TYMS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
